ArticleResearch and practice in thrombosis and haemostasis2025

Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' Organisation.

Caroline Wall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.